Annoviant Gets Grant to Develop Cardiac Device

Atlanta, Ga.-based Annoviant has been awarded a two-year, $1.85 million grant to help it develop and prepare to market its TxGuard pulmonary-valved conduit.

The device, which is for treatment of congenital heart disease — mainly in pediatric patients — uses materials designed to allow regeneration with host cells, enabling the device to grow with children.

In the U.S., an estimated 2,500 newborns are born each year with a heart defect that requires the use of a substitute conduit artery.

The grant from the National Institutes of Health is an extension of a technology transfer grant the company received in 2019.